Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6126086 | 0.85 | ACHE (0.52) | ACHEHTR2AALDH1A1CYP3A4GAA | |
| SCHEMBL9116596 | 0.82 | ACHE (0.46) | ACHEHTR2AALDH1A1CYP3A4 | |
| SCHEMBL26922425 | 0.82 | HTR2A (0.53) | ACHEHTR2AALDH1A1CYP3A4 | |
| SCHEMBL309617 | 0.81 | ALDH1A1 (0.61) | ALDH1A1GAA | |
| SCHEMBL16056216 | 0.81 | ACHE (0.44) | ACHEHTR2AALDH1A1CYP3A4 | |
| SCHEMBL4960829 | 0.81 | HTR2A (0.74) | HTR2AGAA | |
| SCHEMBL10148127 | 0.81 | HTR2A (0.50) | HTR2AALDH1A1GAA | |
| SCHEMBL3207574 | 0.80 | ACHE (0.56) | ACHEALDH1A1CYP3A4GAA | |
| SCHEMBL24899349 | 0.80 | SLC13A5 (0.49) | ACHEHTR2AALDH1A1 | |
| SCHEMBL11288361 | 0.79 | ACHE (0.60) | ACHEALDH1A1CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | ACHE 92/4885HTR2A 1695/4885ALDH1A1 1257/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | ACHE 4486/4885HTR2A 4330/4885ALDH1A1 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.